Surgical Resection After Preoperative Chemoradiotherapy Benefits Selected Patients With Unresectable Pancreatic Cancer
Authors:
- Javier AristuJAJavier Aristu
- Rosa CañónRCRosa Cañón
- Fernando PardoFPFernando Pardo
- Rafael Martínez-MongeRMRafael Martínez-Monge
- Salvador Martin-AlgarraSMSalvador Martin-Algarra
- José Manuel OrdoñezJOJosé Manuel Ordoñez
- Elena VillafrancaEVElena Villafranca
- Marta MorenoMMMarta Moreno
- Mauricio CambeiroMCMauricio Cambeiro
- Ignacio AzinovicIAIgnacio Azinovic
- 1 February 2003
- journal article
- clinical trial
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 26 (1) , 30-36
Abstract
Simultaneous chemoradiation is used in unresectable pancreatic cancer for palliation. It is not known if the use of adjuvant surgery will benefit this group of patients. From November 1991 to September 1998, 47 patients with unresectable pancreatic cancer were treated with simultaneous preoperative radiation therapy (45 Gy) and chemotherapy. Chemotherapy followed three different protocols: cisplatin, 5-fluorouracil ± paclitaxel; cisplatin, 5-fluorouracil (protracted infusion); and docetaxel and gemcitabine. Whipple pancreatoduodenectomy was performed 1 month after the end of radiation in patients selected for resection. Twenty-three unresectable tumors after preoperative treatment (47%) received an additional dose (10–12 Gy) of radiotherapy using intraoperative or external radiation therapy. Twelve patients (26%) were considered to have clinically resectable tumors after the preoperative treatment. Nine patients had surgery (19% of the total number of patients), and 2 of them had complete pathologic response. After chemoradiation, two patients died of pneumonia and gastrointestinal bleeding, respectively, and another two patients died in the postoperative period. Local recurrence was observed in 22% of the patients and 57% had distant metastases. Three-year survival rates for patients with unresectable and resectable tumors was 0% (median survival 10 months) and 48% (median survival 23 months), respectively (p = 0.0004). Preoperative treatment with chemotherapy and radiotherapy in patients with unresectable pancreatic cancer is feasible. In some patients, the tumor can be resected, and in addition some cases of complete pathologic response were found. Long-term survivors were observed in the group of resected tumors. More effective chemotherapy regimens are needed because the majority of the patients died of metastatic disease.Keywords
This publication has 22 references indexed in Scilit:
- Chemoradiotherapy as preoperative treatment in locally advanced unresectable pancreatic cancer patients: results of a feasibility studyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1999
- Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic headThe American Journal of Surgery, 1996
- Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European organization for research and treatment of cancer (EORTC)International Journal of Radiation Oncology - Biology - Physics (IJROBP), 1995
- Preoperative chemoradiation for adenocarcinoma of the pancreas and duodenumInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1994
- Neoadjuvant Therapy for Unresectable Pancreatic AdenocarcinomaArchives of Surgery, 1993
- Resection Margins in Carcinoma of the Head of the PancreasAnnals of Surgery, 1993
- Preoperative Chemoradiation and Pancreaticoduodenectomy for Adenocarcinoma of the PancreasArchives of Surgery, 1992
- Treatment of Locally Unresectable Carcinoma of the Pancreas: Comparison of Combined-Modality Therapy (Chemotheraphy Plus Radiotherapy) to Chemotheraphy Alone1JNCI: Journal of the National Cancer Institute, 1988
- COMBINED 5-FLUOROURACIL AND SUPERVOLTAGE RADIATION THERAPY OF LOCALLY UNRESECTABLE GASTROINTESTINAL CANCERThe Lancet, 1969
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958